Table S3. Summary of significant differences in the reporting of all grades and severe (CTCAE: grade ≥3) all-causality adverse events between days 0–90 from first 90Y-RE procedure in patients with and without abnormal laboratory parameters.
| Parameter | System organ, class | Baseline grade 0, n (%) | Baseline grade ≥1, n (%) | P value for all grades† | P value for grade ≥3‡ | |||
|---|---|---|---|---|---|---|---|---|
| CTCAE grade | All grades | Grade ≥3 | All grades | Grade ≥3 | ||||
| Baseline bilirubin, grade 0 (n=556), grade ≥1 (n=37) | Total patients | 375 (67.4) | 96 (17.3) | 26 (70.3) | 13 (35.1) | 0.856 | 0.014 | |
| Constitutional | 252 (45.3) | 27 (4.9) | 15 (40.5) | 6 (16.2) | 0.612 | 0.012 | ||
| Fatigue | 234 (42.1) | 23 (4.1) | 14 (37.8) | 6 (16.2) | 0.731 | 0.006 | ||
| Psychiatric | 40 (7.2) | 4 (0.7) | 7 (18.9) | 1 (2.7) | 0.020 | 0.276 | ||
| Anorexia nervosa | 39 (7.0) | 4 (0.7) | 7 (18.9) | 1 (2.7) | 0.018 | 0.276 | ||
| Hepatobiliary | 65 (11.7) | 27 (4.9) | 14 (37.8) | 7 (18.9) | <0.001 | 0.003 | ||
| Hyperbilirubinemia | 43 (7.7) | 14 (2.5) | 11 (29.7) | 3 (8.1) | <0.001 | 0.083 | ||
| Ascites | 16 (2.9) | 9 (1.6) | 4 (10.8) | 2 (5.4) | 0.030 | 0.146 | ||
| REILD | 7 (1.3) | 1 (0.2) | 3 (8.1) | 2 (5.4) | 0.020 | 0.011 | ||
| Hepatic failure | 2 (0.4) | 0 | 2 (5.4) | 2 (5.4) | 0.021 | 0.004 | ||
| Baseline albumin, grade 0 (n=392), grade ≥1 (n=199) | Total patients | 261 (66.6) | 61 (15.6) | 138 (69.3) | 48 (24.1) | 0.517 | 0.013 | |
| Intestinal obstruction | 1 (0.3) | 1 (0.3) | 4 (2.0) | 3 (1.5) | 0.046 | 0.113 | ||
| Constitutional | 176 (44.9) | 16 (4.1) | 90 (45.2) | 17 (8.5) | 1.000 | 0.036 | ||
| Fatigue | 164 (41.8) | 14 (3.6) | 83 (41.7) | 15 (7.5) | 1.000 | 0.043 | ||
| Hepatobiliary | 45 (11.5) | 16 (4.1) | 33 (16.6) | 18 (9.0) | 0.095 | 0.023 | ||
| Hyperbilirubinemia | 26 (6.6) | 6 (1.5) | 27 (13.6) | 11 (5.5) | 0.009 | 0.009 | ||
| Influenza | 11 (2.8) | 0 | 0 | 0 | 0.019 | Na | ||
| Baseline ALP, grade 0 (n=241), grade ≥1 (n=351) | Total patients | 144 (59.8) | 30 (12.4) | 255 (72.6) | 78 (22.2) | 0.001 | 0.002 | |
| Constitutional | 86 (35.7) | 7 (2.9) | 179 (51.0) | 26 (7.4) | <0.001 | 0.018 | ||
| Fatigue | 83 (34.4) | 6 (2.5) | 163 (46.4) | 23 (6.6) | 0.004 | 0.032 | ||
| Fever | 7 (2.9) | 0 | 36 (10.3) | 2 (0.6) | <0.001 | 0.516 | ||
| Psychiatric | 12 (5.0) | 3 (1.2) | 34 (9.7) | 2 (0.6) | 0.042 | 0.402 | ||
| Hepatobiliary | 17 (7.1) | 9 (3.7) | 61 (17.4) | 24 (6.8) | <0.001 | 0.144 | ||
| Hyperbilirubinemia | 8 (3.3) | 5 (2.1) | 45 (12.8) | 12 (3.4) | <0.001 | 0.455 | ||
| Baseline ALT, grade 0 (n=409), grade ≥1 (n=175) | Total patients | 270 (66.0) | 70 (17.1) | 124 (70.9) | 36 (20.6) | 0.289 | 0.349 | |
| Fever | 24 (5.9) | 2 (0.5) | 19 (10.9) | 0 | 0.039 | 1.000 | ||
| Hepatobiliary | 45 (11.0) | 20 (4.9) | 33 (18.9) | 13 (7.4) | 0.016 | 0.242 | ||
| Hyperbilirubinemia | 28 (6.8) | 11 (2.7) | 25 (14.3) | 6 (3.4) | 0.007 | 0.600 | ||
| Baseline AST, grade 0 (n=296), grade ≥1 (n=294) | Total patients | 186 (62.8) | 41 (13.9) | 212 (72.1) | 67 (22.8) | 0.018 | 0.006 | |
| Constitutional | 119 (40.2) | 8 (2.7) | 146 (49.7) | 25 (8.5) | 0.025 | 0.002 | ||
| Fatigue | 112 (37.8) | 7 (2.4) | 134 (45.6) | 22 (7.5) | 0.066 | 0.004 | ||
| Hepatobiliary | 23 (7.8) | 11 (3.7) | 54 (18.4) | 22 (7.5) | <0.001 | 0.050 | ||
| Hyperbilirubinemia | 12 (4.1) | 6 (2.0) | 40 (13.6) | 11 (3.7) | <0.001 | 0.230 | ||
| Baseline hemoglobin, grade 0 (n=356), grade ≥1 (n=238) | Total patients | 239 (67.1) | 62 (17.4) | 159 (66.8) | 47 (19.7) | 0.929 | 0.517 | |
| Gastrointestinal | 191 (53.7) | 31 (8.7) | 106 (44.5) | 20 (8.4) | 0.036 | 1.000 | ||
| Abdominal pain | 146 (41.0) | 19 (5.3) | 73 (30.7) | 11 (4.6) | 0.012 | 0.849 | ||
| Nausea | 111 (31.2) | 4 (1.1) | 50 (21.0) | 2 (0.8) | 0.006 | 1.000 | ||
†, P value across all grades, Fisher’s Exact Test; ‡, P value for grades ≥3, Fisher’s Exact Test. ALT, alanine transaminase; AST, aspartate aminotransferase; CTCAEs, Common Terminology Criteria Adverse Events; RE, radioembolization.